



17 | Suppl.

T. S. &

PTO/SB/08 (2/92)

Sheet Page 1 of 1

	•		- Direct 1	- 14	
	FORM PTO-1449	Docket No. GZ 2065.23	Appl. No. 09/909,7	万	_
OIF	INFORMATION DISCLOSURE STATEMENT	·			JAN 3
HAL	21 7003 (use several sheets if necessary)	Applicant(s) Susan Sch	niavi, et al.	R 1600/	0 2003
BANK	CAMPATA STATE OF THE STATE OF T	Filing Date: July 19, 2001	Group Art Unit: 1635) <u>7900</u>	
79 €	TRAUD -				

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	TRANS	LAT'N
0							yes	no
XX	1.	22 Mar. 2001	WO 01/19855	American Home Prod.			ļ	
İ					<u> </u>			

OTHER DOCUMENTS

List	2.	Cai Qiang, et al., "Brief Report: Inhibition of Renal Phosphate Transport By a Tumor Product in a Patient with Oncogenic Osteomalacia" (1994) New England Journal of Medicine Vol. 330: 1645-1649
20	3.	Kumar R., "Phosphatonin-a new phosphaturetic hormone? (Lessons from tumor-induced osteomalacia and X-linked hypophosphataemia)" (1997) Nephrology Dialysis Transplant Vol. 12: 11-13

EXAMINER Jun 1	DATE CONSIDERED $3/17/03$
EXAMINER: Initial if reference considered, whether or not cita citation if not in conformance and not considered. Include a cop	

PTO/SB/08A (10-01)

ct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form1449A-PTO

(use as many sheets as necessary)

•	•		• •
Sheet	1	of	1

Complete if Known					
Application Number	09/909,775				
Filing Date	July 19 2001				
First Named Inventor	Susan Schiavi				
Art Unit	1646 1635				
Examiner Name	Not Yet Assigned Cible				
Attorney Docket Number	GZ 2065.23				

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
199	1	US-5,695,937	12/09/97	Kenneth W. Kinzler et al.		
		US-			RECEIVED	
		US-			NECLIVED	
		US-			MAY 0 3 2002	
		US-			MAY 0 3 2002	
		US-				
		US-			TECH CENTER 1600/29	

Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	1
Initials*	No. ¹	Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	MM-DD-YY	Application of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т
1	2.	WO 00/75280	14.12.00	Lark et al		
						-
						F
						1
· 						╁-

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

4/22/02 11:59 AM 52076671.1/19442-7201

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

.

are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction

Substitute for form1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known				
Application Number	09/909,775			
Filing Date	July 19, 2001			
First Named Inventor	Susan Schiavi			
Art Unit	1646 635			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	GZ 2065.23			

			_
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	
		senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	
(M) 1		HILLIER, L. et al. "Generation and Analysis of 280,000 Human Expressed Sequence Tags" (1997) Genome Res.,	
		Vol. 6, pp. 807-828	
•	2	HOANG, B. et al. "Primary Structure and Tissue Distribution of FRZB, a Novel Protein Related to Drosophila	
		Frizzled, Suggest a Role in Skeletal Morphogenesis" (1996) J. Biol. Chem., Vol. 271, No. 42, pp. 26131-26137	
	3	HUGHES, S. et al. "Shared Phenotyic Expression of Osteoblasts and Chondrocytes in Fracture Callus" (1995) J.	
		Bone Miner. Res., Vol. 10, No. 4, pp. 533-544	
	4	KUMAR, R. "Phosphatonin – a new phosphaturetic hormone? (Lessons from Tumour-induced osteomalacia and X-	
		linked hypophosphataemia)" (1997) Nephrol. Dial. Transplant, Vol. 12, pp. 11-13.	
	5 .	LEYNS, L. et al. "Frzb-1 Is a Secreted Antagonist of Wnt Signaling Expressed in the Spemann Organizer" (1997)	
		Cell, Vol. 88, pp. 747-756	
	6	MOON, R. et al. "Structurally Related Receptors and Antagonists Compete for Secreted Wnt Ligands" (1997) Cell,	
		Vol. 88, pp. 725-728	
	7	RATTNER, A. et al. "A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of	
		frizzled receptors" (1997) PNAS, Vol. 94, pp. 2859-2863	
	8	ROWE, P. "Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia" (1994) Hum. Genet., Vol	
		94, pp. 457-467.	<u> </u>
1	9	ROWE, P. "The PEXGene: Its Role in X-Linked Rickets, Osteomalacia, and Bone Mineral Metabolism" (1997) Exp.	
		Nephrol, Vol. 5, pp. 355-363.	_
	10	STONE, D. et al "The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog" (1996)	
	ļ	Science, Vol. 384, pp. 129-134	_
	11	VELCULESCU, V. et al. "Serial Analysis of Gene Expression" (1995) Science, Vol. 270, pp. 484-487	_
1	12	VORTKAMP, A. et al. "Regulation of Rate of Cartilage Differentiation by Indian Hedgehog and PTH-Related Protein"	
	ļ	(1996) Science, Vol. 273, pp. 613-622	_
	13	WANG, S. et al. "Frzb, a Secreted Protein Expressed in the Spemann Organizer, Binds and Inhibits Wnt-8" (1997)	
to T	ļ	Cell, Vol. 88, pp. 757-766	
	14	PECEIVE	Ξ
	15	TILOE.	_
	16	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	θ
	17	MAI 0 0	

	-	_	 		
Examiner's Signature	Harr	Seco	Date Considered	3/18/03	TECH CENTER 1600/2900
Signature	17004		 Considered	2/10/02	

52076871.1/19442-7201 4/22/02 11:59 AM

[•] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.